Skip to content

Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery

Early Onset Malignancies Initiative (EOMI): Molecular Profiling of Breast, Colon, Kidney, Liver, Multiple Myeloma, and Prostate Among Racially and Ethnically Diverse Populations

Status
Suspended
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04955808
Enrollment
2400
Registered
2021-07-09
Start date
2017-02-07
Completion date
2026-12-31
Last updated
2026-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Carcinoma, Colon Carcinoma, Invasive Carcinoma, Kidney Carcinoma, Liver Carcinoma, Malignant Solid Neoplasm, Multiple Myeloma, Prostate Carcinoma

Brief summary

This research trial studies how well biospecimen collection works in identifying genetic changes in patients with breast, prostate, colorectal, liver, or kidney cancer or multiple myeloma undergoing surgery. Studying samples collected during surgery may add to the understanding of cancer by looking for the genetic changes that cause early cancer onset in people of certain racial and ethnic groups.

Detailed description

PRIMARY OBJECTIVE: I. To acquire tissue and blood, and other biospecimens for research purposes during procedures for clinical care to accelerate our understanding of the molecular basis of early onset cancers occurring in racial and/or ethnic minority populations through the application of genome analysis technologies, including large- scale genome sequencing and clinical data analysis. OUTLINE: Patients undergo collection of tumor tissue during surgery. Patients also undergo blood samples. Samples collected may undergo genetic analysis including whole exome sequencing. After completion of study, patients are followed for up at 6 and 12 months.

Interventions

PROCEDUREBiospecimen Collection

Undergo collection of tissue and blood samples

OTHERLaboratory Biomarker Analysis

Correlative studies

Sponsors

National Cancer Institute (NCI)
Lead SponsorNIH

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with either: * Histologically confirmed invasive carcinoma or multiple myeloma OR * Clinical diagnosis of carcinoma or multiple myeloma OR * Suspected clinical diagnosis of multiple myeloma * Patients with one of following tumor types and age ranges: * Breast cancer diagnosis at ages 18-45 * Colon cancer diagnosis at ages 18-55 * Kidney cancer at diagnosis at ages 18-50 (American Indian or Alaska Native \[AIAN\] and non-Hispanic Whites \[NHW\] only) * Liver cancer diagnosis at ages 18-55 * Prostate cancer diagnosis at ages 18-55 * Multiple myeloma diagnosis at ages 18-50 * Patients whose tumor specimen was collected or will be collected during one of the following routine procedures: * Surgery to remove cancer OR * Routine biopsy procedures performed to confirm a histologic diagnosis OR * Routine biopsy procedure performed to obtain additional tumor material for routine prognostic or predictive biomarkers OR * Routine procedure to place a vascular access device prior for systemic therapy * Patients who have received no therapy for their cancer other than surgery, irrespective of stage * Collection of specimens from living patients: * Ability to understand and willingness to sign a written informed consent document indicating their willingness to have their tissue or biologic fluid specimens used for research as outlined in this protocol * Collection of specimens from deceased patients: * Banked tissue samples and/or banked biologic fluid specimens of deceased patients may be used as long as all samples or specimens are properly de- identified prior to submission * Sites must use the Central Institutional Review Board for the National Cancer Institute (NCI CIRB).

Exclusion criteria

* Patients who do not meet criteria for an early onset malignancy * Prior systemic therapy or radiation therapy for their malignancy * Tumor does not meet quality metrics * Patient refused consent for use of tissue for research activities included in the Early Onset Malignancies Initiative * A diagnosis of a synchronous invasive malignancy * Patients with a history of invasive cancer or hematologic malignancy in preceding 5 years

Design outcomes

Primary

MeasureTime frameDescription
Acquisition of tissue, blood, and other biospecimens for research purposesUp to 3 yearsWill be performed.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORMichelle Bennett

National Cancer Institute Division of Cancer Prevention

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 14, 2026